Whey Protein Formula With Medium Chain Triglycerides, Carbohydrate, Vitamins And Minerals
Deferred MetabolicRestrictedNot applicable line
Dietary management of conditions requiring a source of medium chain triglycerides in infants with fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders.
1
Submissions
2016–16
On the record
—
ICER range
Cost-min
Cost basis
From the public summary
PBAC outcome
6.1 The PBAC deferred its decision on listing Infatrini Peptisorb® as a Restricted Benefit for the dietary management of conditions requiring a source of medium chain triglycerides. The PBAC considered that the main comparator was unsuitable due to the discrepancies in nutritional composition to Monogen®. 4PSD · Jul 2016
6.2 The PBAC noted the advice of the NPWP that supported deferring the decision on listing Infatrini Peptisorb® on the PBS.PSD · Jul 2016
Cost-effectiveness
Minor submission with no economic evaluation; cost comparison basis only (cost per kilojoule of energy).
Economic model disputed
Decision context
PopulationInfants aged newborn up to 18 months (or up to 9 kg) with fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2016 | Deferred | Monogen® (primary); Peptamen Junior® (secondary) | — | Cost-minimisation · Cost-minimisation |
Similar precedents
Medium Chain Triglycerides Formula89%Medium Chain Triglycerides; Protein Formula With Carbohydrate, Fat, Vitamins And Minerals84%Triglycerides Medium Chain Formula82%Protein Hydrolysate Formula With Medium Chain Triglycerides76%Amino Acid Formula With Fat, Carbohydrate, Vitamins, Minerals, Trace Elements And Medium Chain Triglycerides71%Triglycerides, Long Chain; Triglycerides, Medium Chain71%Triglycerides Medium Chain And Long Chain With Glucose Polymer69%Triglycerides, Medium Chain68%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to specific fat malabsorption conditions (liver disease, short gut syndrome, cystic fibrosis, GI disorders) and age limit (newborn to 18 months/9 kg) within broader TGA label.